🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

127 results for “Jin” Clear

  1. LUCAR-20SP cells

    Nanjing Legend Biotech Co.

    Relapsed B-cell Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  2. LUCAR-B68 cells product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  3. LUCAR-DKS1 NK cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  4. LUCAR-G39D cells product

    Nanjing Legend Biotech Co.

    B-Cell Non-Hodgkin Lymphoma-Recurrent

    phase 1 mab active

    1 trial

  5. LUCAR-G79 T cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  6. LUCAR-G79D T cells

    Nanjing Legend Biotech Co.

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  7. LVIVO-TaVec400 product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)

    phase 1 mab active

    1 trial

  8. NTQ5082 capsule

    Nanjing Chia-tai Tianqing Pharmaceutical

    Complement-mediated Hemolytic Diseases

    phase 1 small molecule active

    1 trial

  9. OPB-31121

    Otsuka Beijing Research Institute

    Non-Hodgkin's Lymphoma(NHL)

    phase 1 small molecule completed

    1 trial

  10. OPC-108459

    Otsuka Beijing Research Institute

    Atrial Fibrillation

    phase 1 small molecule completed

    1 trial

  11. QT-019C

    Tianjin Huanhu Hospital

    Neuromyelitis Optica Spectrum Disorders

    phase 1 small molecule active

    1 trial

  12. RJK-RT2831 dose-escalation phase Ia

    Nanjing Zenshine Pharmaceuticals

    Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  13. TQB2101 for Injection

    Nanjing Zenshine Pharmaceuticals

    Advanced Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  14. Tolvaptan 15mg or 30mg or 60mg or Placebo

    Otsuka Beijing Research Institute

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Vagus Nerve Stimulation

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Refractory Epilepsy

    phase 1 other active

    1 trial

  16. YN001

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Cardiovascular Diseases

    phase 1 small molecule completed

    1 trial

  17. anti-CD123 CAR-T treatment

    Nanjing Legend Biotech Co.

    Acute Leukemia

    phase 1 small molecule terminated

    1 trial

  18. Aripiprazole

    Otsuka Beijing Research Institute

    Schizophrenia

    approved small molecule completed

    3 trials

  19. Cilostazol

    Otsuka Beijing Research Institute

    Polyneuropathy

    approved small molecule completed

    1 trial

  20. Cilostazol

    Otsuka Beijing Research Institute

    Cerebral Infarction

    approved small molecule completed

    1 trial

  21. Dexamethasone

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Localized Primary Osteoarthritis of Both Hips (Diagnosis)

    approved small molecule active

    1 trial

  22. FuKe Qianjin Capsules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Endometritis

    approved small molecule active

    1 trial

  23. Hepatitis B vaccine

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Hepatitis B Vaccination, HIV

    approved mab active

    1 trial

  24. Metformin

    Xijing Hospital of Digestive Diseases

    Gastric Intestinal Metaplasia

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources